Patents Assigned to Pierre Fabre Medicament
  • Patent number: 10842789
    Abstract: The present invention relates to a method of treating schizophrenia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a selective D3 antagonist, wherein said subject has at least one negative symptom (NS) among the following core negative symptoms in PANSS: Blunted Affect (N1), Emotional Withdrawal (N2), Poor Rapport (N3), Passive withdrawal (N4), and Lack of Spontaneity (N6); with moderate or higher severity. Methods for improving the probability of success and/or the effect of a treatment of schizophrenia in a subject in need thereof are also described.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: November 24, 2020
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Françoise Tonner, Armida Mucci
  • Publication number: 20200308242
    Abstract: The present invention relates to new immunocytokines which are useful for the treatment of cancer. These fusion proteins comprise (i) an antibody or antigen-binding fragment thereof fused to (ii) a cleavable peptide linker, and (iii) cytokine, or functional fragments thereof. Methods of treatment using these immunocytokines are also disclosed.
    Type: Application
    Filed: April 1, 2020
    Publication date: October 1, 2020
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Peter LOWE, Jean-François HAEUW, Alicia CONTET, Céline BERTAUX, Barbara AKLA, Marie-Claire JANIN-BUSSAT
  • Patent number: 10766959
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: September 8, 2020
    Assignee: Pierre Fabre Medicament
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sung Young Kim, Leonard G Presta, Jan-Willem Theunissen
  • Publication number: 20200270352
    Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Application
    Filed: February 26, 2020
    Publication date: August 27, 2020
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW, Thierry CHAMPION, Alain ROBERT, Marie LAMOTHE
  • Patent number: 10753937
    Abstract: The present disclosure relates to IGF-IR (insulin like growth factor receptor-1) antibodies characterized by CDR sequences a, to be used in detection methods of IGF-IR expressing tumoral cells.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: August 25, 2020
    Assignee: Pierre Fabre Medicament
    Inventor: Alexandra Jouhanneaud
  • Publication number: 20200138888
    Abstract: The invention relates to a compound selected from among celastrol, the derivatives thereof and the pharmaceutically acceptable salts of celastrol and its derivatives, or a composition comprising such a compound for use in the topical prevention and/or treatment of a tumour or precancerous disease of the skin.
    Type: Application
    Filed: February 17, 2017
    Publication date: May 7, 2020
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Thien NGUYEN, Arnaud PILLON
  • Publication number: 20200138800
    Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, wherein the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
    Type: Application
    Filed: December 17, 2019
    Publication date: May 7, 2020
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Bruno PAILLARD, Laurence DEL FRARI, Valérie BRUNNER, Adrian NEWMAN TANCREDI, Mark VARNEY
  • Patent number: 10633448
    Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: April 28, 2020
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Thierry Champion, Alain Robert, Marie Lamothe
  • Publication number: 20200093879
    Abstract: The invention relates to a use of Copaifera oleoresin for producing a medicament for preventing and/or treating pathologies of the prostate, particularly benign prostatic hyperplasia and/or prostate cancer.
    Type: Application
    Filed: March 20, 2018
    Publication date: March 26, 2020
    Applicant: PIERRE FABRE MEDICAMENT
    Inventor: Christel FIORINI-PUYBARET
  • Publication number: 20200040102
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Application
    Filed: July 23, 2019
    Publication date: February 6, 2020
    Applicant: Pierre Fabre Medicament
    Inventors: John LIPPINCOTT, Edward Thein Htun VAN DER HORST, Sun Young KIM, Leonard G. PRESTA
  • Patent number: 10548885
    Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, where in the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: February 4, 2020
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Bruno Paillard, Laurence Del Frari, Valérie Brunner, Adrian Newman Tancredi, Mark Varney
  • Patent number: 10544156
    Abstract: The invention concerns a compound of the following formula (I) or a pharmaceutically acceptable salt or solvate thereof as well as a pharmaceutical composition containing such a compound, and the use of such a compound as a drug, notably as a DNMT inhibitor, in particular in the treatment of cancer.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: January 28, 2020
    Assignees: PIERRE FABRE MEDICAMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Ludovic Halby, Yoann Menon, El Bachir Kaloun, Christophe Long, Paola B. Arimondo
  • Publication number: 20200010414
    Abstract: The present invention concerns a compound of following formula (1): where: —R1 is H or OH, —R2 is a (C1-C6)alkyl, COOH, COO—((C1-C6)alkyl) or thiazolyl group, —R3 is H or a (C1-C6)alkyl group, and —R4 is: ?a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms substituted by one or more groups chosen from among OH and NR5R6, ?—(CH2CH2X1)(CH2CH2X2)a2(CH2CH2X3)a3(CH2CH2X4)a4(CH2CH2X5)a5R7, ?an aryl-(C1-C8)alkyl group substituted by one N or more groups chosen from among OH and NR9R10 groups, or ?a heterocycle-(C1-C8)alkyl group optionally substituted by one or C more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.
    Type: Application
    Filed: May 30, 2019
    Publication date: January 9, 2020
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Michel PEREZ, Ian RILATT, Marie LAMOTHE
  • Patent number: 10519125
    Abstract: The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: December 31, 2019
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Frédéric Marion, El Bachir Kaloun, Frédéric Lieby-Muller, Michel Perez, Jean-Philippe Annereau, Laurent Creancier
  • Patent number: 10517863
    Abstract: Trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues as DNMT inhibitors for use as a drug for the treatment of cancer and neurological diseases and for cell reprogramming, in particular to prime for chemotherapy or immunotherapy.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: December 31, 2019
    Assignees: PIERRE FABRE MEDICAMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Yoann Menon, Christophe Long, François Sautel, Paola B. Arimondo
  • Publication number: 20190359717
    Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.
    Type: Application
    Filed: January 4, 2019
    Publication date: November 28, 2019
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Liliane GOETSCH, Thierry WURCH, Cédric BES
  • Publication number: 20190330353
    Abstract: The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
    Type: Application
    Filed: December 18, 2018
    Publication date: October 31, 2019
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Liliane GOETSCH, Matthieu Broussas, Charlotte BEAU-LARVOR, Thierry Champion, Alain Robert
  • Patent number: 10457734
    Abstract: The present disclosure relates to a novel antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: October 29, 2019
    Assignee: PIERRE FABRE MEDICAMENT
    Inventor: Alexandra Jouhanneaud
  • Patent number: 10450299
    Abstract: The present invention relates to compounds of the following formula (I) and pharmaceutically acceptable salts and solvates thereof, their methods of preparation, their use as a drug, notably in the treatment of cancer, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: October 22, 2019
    Assignees: Centre National de la Recherche Scientifique (CNRS), Pierre Fabre Medicament, Sapienza Universita di Roma
    Inventors: Ludovic Halby, Paola Arimondo, Antonello Mai, Dante Rotili
  • Publication number: 20190307741
    Abstract: The present invention relates to a pharmaceutical combination comprising: (a) vinflunine or a pharmaceutically acceptable salt thereof, and (b) at least one PD1-inhibitor and/or at least one PD-L1-inhibitor or pharmaceutically acceptable salt thereof. Such a pharmaceutical combination is useful as a drug, notably in the treatment of a proliferative disease, such as cancer.
    Type: Application
    Filed: July 6, 2017
    Publication date: October 10, 2019
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Anna KRUCZYNSKI, Isabelle VANDENBERGHE, Pierre FERRE